Show simple item record

dc.contributor.authorMostafid, AHen_US
dc.contributor.authorPorta, Nen_US
dc.contributor.authorCresswell, Jen_US
dc.contributor.authorGriffiths, TRLen_US
dc.contributor.authorKelly, JDen_US
dc.contributor.authorPenegar, SRen_US
dc.contributor.authorDavenport, Ken_US
dc.contributor.authorMcGrath, JSen_US
dc.contributor.authorCampain, Nen_US
dc.contributor.authorCooke, Pen_US
dc.contributor.authorMasood, Sen_US
dc.contributor.authorKnowles, MAen_US
dc.contributor.authorFeber, Aen_US
dc.contributor.authorKnight, Aen_US
dc.contributor.authorCatto, JWFen_US
dc.contributor.authorLewis, Ren_US
dc.contributor.authorHall, Een_US
dc.identifier.citationBJU international, 2020, 125 (6), pp. 817 - 826en_US
dc.description.abstractOBJECTIVES:To evaluate the activity of intravesical mitomycin-C (MMC) to ablate recurrent low-risk non-muscle-invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of recurrence. PATIENTS AND METHODS:CALIBER is a phase II feasibility study. Participants were randomized (2:1) to treatment with four once-weekly MMC 40-mg intravesical instillations (chemoablation arm) or to surgical management. The surgical group was included to assess the feasibility of randomization. The primary endpoint was complete response to intravesical MMC in the chemoablation arm at 3 months, reported with exact 95% confidence intervals (CIs). Secondary endpoints included time to subsequent recurrence, summarized by Kaplan-Meier methods. RESULTS:Between February 2015 and August 2017, 82 patients with visual diagnosis of recurrent low-risk NMIBC were enrolled from 24 UK hospitals (chemoablation, n = 54; surgical management, n =28). The median follow-up was 24 months. Complete response at 3 months was 37.0% (20/54; 95% CI 24.3-51.3) with chemoablation and 80.8% (21/26; 95% CI 60.6-93.4) with surgical management. Amongst patients with complete response at 3 months, a similar proportion was recurrence-free by 12 months in both groups (84%). Amongst those with residual disease at 3 months, the 12-month recurrence-free proportion was lower in the surgical management group (40.0%) than in the chemoablation group (84%). Recruitment stopped early as chemoablation did not meet the prespecified threshold of 45% complete responses at 3 months. CONCLUSION:Intravesical chemoablation in low-risk NMIBC is feasible and safe, but did not demonstrate sufficient response in the present trial. After chemoablation there may be a reduction in recurrence rate, even in non-responders, that is greater than with surgery alone. Further research is required to investigate the role and optimal schedule of neoadjuvant intravesical chemotherapy prior to surgery for NMIBC.en_US
dc.format.extent817 - 826en_US
dc.titleCALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.en_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBJU internationalen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Trials & Statistics Uniten_US
icr.researchteamICR-CTSU Urology and Head and Neck Trials Teamen_US
dc.contributor.icrauthorHall, Emmaen_US
dc.contributor.icrauthorPorta, Nuriaen_US
dc.contributor.icrauthorPenegar, Stevenen_US
dc.contributor.icrauthorLewis, Rebeccaen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as